Navigation Links
Microbix' Pipeline Set To Reach Milestones In 2010
Date:12/16/2009

--

Early in November, Microbix announced that KINLYTIC (urokinase for injection) was approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide. Later that month, Microbix announced a marketing and supply agreement with Riso Pharma that guarantees purchases of not less than 50,000 KINLYTIC vials over the next three years. Urokinase sales are projected to begin in Canada and other countries in the second half of 2010.

Under the terms of the agreement with Riso, Microbix granted exclusive rights to market KINLYTIC throughout the Middle East. Riso will be responsible for all commercialization activities and purchase inventory for distribution.

The Company's $2.5 million acquisition in 2008 of all Urokinase assets from ImaRx Therapeutics, Inc. of Tucson, Arizona, ( IMRX) resulted in a major transformation for Microbix. With this acquisition, Microbix will become a fully integrated biopharmaceutical company with an established revenue base. Discussions are under way with several potential partners, all in the hospital-based injection market, to help Urokinase reach its full commercial potential.

All partnership agreements will include an up-front payment for marketing and/or development rights plus ongoing milestone and royalty payments.

Urokinase, which Microbix has re-branded as KINLYTIC, has been administered to over four million patients and generated peak annual worldwide sales of more than $300 million, prior to Abbott Laboratories discontinuing sales in 1999 due to manufacturing issues. In 2008, Microbix completed the acquisition of all urokinase assets from ImaRx Therapeutics, Inc., making Microbix the only worldwide source of low-molecular-weight urokinase.

According to IMS data, the total Canadian clot-busting market ex
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
6. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
7. Microbix Sales Grow 22% For Nine Months
8. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
9. Microbix Biosystems Provides a Corporate Update
10. Microbix Biosystems Re-files Annual Results With OSC
11. Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... (PRWEB) September 30, 2014 Each ... burn injuries require medical attention. In the military, ... serious complications to battlefield medical care. More than ... and Afghanistan. Burn wounds heal slowly, remain inflamed ... be excessive, physically debilitating and functionally damaging. While ...
(Date:9/29/2014)... Sept. 29, 2014 Research and Markets ... Market by Product & Services, End-User , Application - ... The global oligonucleotide synthesis market is ... million in 2014, growing at a CAGR of 9.8% ... is categorized on the basis of products and services, ...
(Date:9/29/2014)... Research and Markets  has announced the addition of ... Chromatograph Market by Type , Technology, Spectroscopy, Gas chromatography, ... to 2013 - 2020" report to their offering. ... analytical instrument that provides chemical composition data on process ... which companies carry out their production and improve the ...
(Date:9/29/2014)... 2014  Atlas Venture, an early stage venture capital ... today announced that Jason Rhodes , President and ... ), is joining the firm,s life sciences investing team ... At Atlas, Rhodes will work closely with the life ... accomplished record in company creation, deal making and venture ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2
... Calif., Sept. 29, 2011 Ambry Genetics today ... provide CLIA-approved exome services for applications in clinical ... geneticists and medical directors, these results will allow ... have eluded traditional diagnostic approaches. ...
... 29, 2011 Dr. Barrett Bready, CEO of NABsys, ... Year. Dr. Bready will be honored at a ceremony ... presented by the Providence Business News in partnership with ... Bryant University, Cox Business, Edwards Angell Palmer & Dodge, ...
... system, you probably think about it fighting off a cold. ... immune cells in your brain may contribute to how you ... 10,000 years of using alcohol, and several decades of investigation ... our brain, we are still trying to figure out exactly ...
Cached Biology Technology:Ambry Genetics First to Offer Exome Sequencing Service for Clinical Diagnostics. 2NABsys CEO Barrett Bready Named Rhode Island Innovator of the Year 2Alcohol-related behavior changes -- blame your immune system 2
(Date:9/29/2014)... from the skeleton of a man who lived 2,330 years ... ourselves as humans? A great deal when his DNA profile ... terms found to-date in a region where modern humans ... , The man,s maternal DNA, or ,mitochondrial DNA, was sequenced ... Mitochondrial DNA provided the first evidence that we all come ...
(Date:9/29/2014)... -- NXT-ID, Inc. (Nasdaq: NXTD and ... focused on the growing mobile commerce market, today announced ... the Company,s Vice-President and Chief Financial Officer effective immediately. ... Financial Officer. Mr. Pereira will continue to serve as ... Mr. Miceli, age 56, has extensive hands ...
(Date:9/29/2014)... were able to safely tolerate treatment with cells cultured ... today in the journal Multiple Sclerosis and Related ... its kind, was conducted by researchers at Mount Sinai, ... at several other institutions. , While designed to ... data also suggested that a preparation of cultured cells ...
Breaking Biology News(10 mins):Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3Cells from placentas safe for patients with multiple sclerosis 2
... A team led by the University of Colorado Boulder has been ... Energy to research modifying E. coli to produce biofuels ... take what we have worked on for the past decade to ... CU-Boulder,s Renewable and Sustainable Energy Institute, or RASEI. "In this project, ...
... Ian Bell, PhD, the Louis Block Distinguished Service Professor ... the Kovler Diabetes Center at the University of Chicago, ... 2012 for his pioneering work in understanding the role ... The prize, the world,s largest award for ...
... scientists produce better climate-resistant corn and other food production plants ... what we eat. Kansas State University geneticists and colleagues ... and prioritize the genes in humans, it improved the likelihood ... control quantitate traits in plants, such as how the plants ...
Cached Biology News:CU-led team receives $9.2 million DOE grant to engineer E. coli into biofuels 2University of Chicago's Graeme Bell receives international diabetes prize 2University of Chicago's Graeme Bell receives international diabetes prize 3Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 2Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 3
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, ... ,S-Gal, 0.3 ,Ferric ammonium citrate, 0.5 ... patented, water soluble, autoclavable chromogenic substrate ... S-Gal by -galactosidase generates a black ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
Biology Products: